Search

everythinglearnresearchcommunity

for

Search:↓

Patients with cutaneous lupus are most concerned about self-consciousness, physical symptoms, and disease progression.

Dermal EZH2 controls skin cell development and hair growth in mice.

The study created hair-bearing skin models that lack a key protein for skin layer attachment, limiting their use for certain skin disease research.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

Dermal fibroblasts have adjustable roles in wound healing, with specific cells promoting regeneration or scar formation.

The new drug carriers show promise for better targeting and treating ovarian cancer.

The mTurq2-Col4a1 mouse model shows how the basement membrane develops in live mammals.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Hair oils can worsen seborrheic dermatitis in black patients.

Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.

CD201+ fascia progenitors are essential for wound healing and could be targeted for treating skin conditions.

Scalp cooling therapy helps preserve hair during chemotherapy for most patients.

Low dose methotrexate does not increase hair fall and may reduce it.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Human hair contains more glycosaminoglycans in children than adults, and these compounds decrease with age, possibly affecting hair thickness.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.

Choosing the right model order in brain connectivity analysis can affect the detection of differences between healthy individuals and those with seasonal affective disorder.

PPAR agonists show promise for skin conditions but need more research before being a main treatment.

Different factors affect where drugs are absorbed in the small intestine, which is important for effective medication use.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Many patients on new leukemia drugs had mild to moderate skin reactions.